What Natera Holders Bought Into

Simply Wall St · 21h ago

If Natera sat on your watchlist instead of in your account over the past year, the outcome may feel like a missed shot. Investors who held Natera over the past year are up 28.5%, including dividends. That move came as the diagnostics group pushed further into personalized medicine built on AI and molecular residual disease testing. The real puzzle is whether investors could reasonably have spotted that this business model, and not just another biotech story, might justify such a payoff.

The move put Natera in the middle of this trade. Scan 36 healthcare AI stocks for other companies exposed to it.

The Two Stories Investors Had To Weigh On Natera

The shares cost US$218 at the start of the period, which put every Natera holder in the middle of a live argument about what the business could become.

The bullish narrative saw a personalized medicine leader in the making, with a Fair Value of US$268. This was essentially the price implied if its optimistic assumptions played out, built on 19.9% annual revenue growth and profit margins shifting from a loss to 18.4% over three years.

The more cautious script pinned Fair Value at US$194, again just the level suggested by its own model. It rested on 15.2% yearly revenue growth and profit margins reaching only 3.7%, alongside the risk that heavy R&D and AI spending might keep profitability under pressure.

NasdaqGS:NTRA 1-Year Stock Price Chart
NasdaqGS:NTRA 1-Year Stock Price Chart

What The Evidence Did To The Natera Argument

Regulatory wins for Natera’s Signatera platform in the US, EU and Japan, plus new clinical data across several cancers, backed the bullish view that this is a personalized medicine business rather than a single test story. Reported results also gave both sides something to chew on. Revenue reached US$793.981m and the company still reported a loss of US$59.912m.

Net margin improved from a loss of 14.8% to a loss of 7.5%, so profitability moved in the right direction but did not yet match the upbeat case. The lesson is clear. When a thesis leans on future margin expansion, it is important to track net margin and absolute profit each quarter and test whether they are really converging on the forecast, not just riding higher sales.

What Natera’s Run Leaves You Paying For Now

Natera shares now trade at US$290, after a 28.5% gain over the past year. The analyst consensus Narrative on Simply Wall St views its Fair Value as sitting above that level, based on a specific argument about how its testing franchise could scale.

The Narrative focuses on Natera turning heavy MRD, early detection and pharma or data spending into sustained test volumes and cash generation. The key question is whether ongoing growth in Signatera volumes and related pharma or data contracts can support that higher figure.

"The main thing that has to go right is that Natera converts its heavy MRD and early cancer detection R&D and commercial spend into sustained test volume growth and larger contributions from pharma and data partnerships while keeping free cash flow positive."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Looking One Step Beyond Natera

Natera points you toward cancer detection and treatment built on precision data. The next puzzle is who helps doctors act on those findings.

Hospitals still need drugs, devices and procedures that actually treat the disease. One large healthcare group focuses on prescription medicines and medical technology for that work.

Its portfolio leans into oncology, immunology and neuroscience, problems that overlap with Natera’s testing focus. It also invests in new platforms and earlier stage therapies.

Those efforts could eventually shift where its revenue and margins come from. If precision diagnostics keep spreading, how might that change demand for this kind of broad healthcare platform?

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 20% above its price